Innovation > Generic development

Research and Development in Hungary

 

In a market environment as sharp and as quickly changing as the pharmaceutical market, long-term, steady development cannot be realized without innovation. Research and development has thus for a long time been a central element of our company’s strategy. Our R&D lies on four pillars: our research experience of more than eighty years, about 500 colleagues working in this field, our strong cooperation with Servier and our continuously growing expenses devoted to innovation. We are considered an outstandingly innovative company on a regional level, too: we dedicate one of the largest amounts to R&D among all the companies present in the CEE region. In the 2015/2016 financial year we spent HUF 13.3 billion (EUR 43 million) on research and development.

Our drug development unit has moved to a new plant: in December 2010 the construction of our new, 3500-square-meter Pharmaceutical Development Laboratory & Pilot Plant was finished. The construction of the facility, where our 70 colleagues – chemists, pharmacists and engineers – carry out drug formulation, altogether cost HUF 3.76 billion. By establishing a new plant with cutting-edge technology, we can accelerate our generic product development. In addition to our new plant, in 2012 we also inaugurated new analytical development laboratories in two of our production sites located in Budapest and Körmend that altogether cost nearly HUF 4 billion.

Generic development

 

One of the most important aims of our generic development is to develop such value-added generic products that can provide new alternatives for the patients at a more favorable price than the original product. In the past years we have launched a great number of products that combine the active ingredients of two drugs, have a retard effect or can be taken more easily by the patients.

Several of our products have a better physical or chemical stability or their active ingredient has higher purity than other products available in the market.

Original research

 

Our strong cooperation with our owner, Servier forms the basis of our original research, which is carried out within the framework of a collaboration agreement established on 1 October 2006.

Research has traditionally been in the focus of Servier. The leading private French pharmaceutical company devotes almost 25% of its revenues to R&D. Servier’s most important fields of research are the central nervous system, oncology, the cardiovascular system, rheumatology and metabolic diseases. Nearly 3000 colleagues of Servier work on several R&D projects in the company’s 19 research centers around the world. Servier is one of the most important partners of the French National Health and Medical Research Institute (INSERM) and the French National Scientific Research Centre (CNRS). (www.servier.com, www.servier.hu).

Patents and Registrations

 

By the end of the 2015/2016 financial year, Egis had altogether 3441 drug registrations: 3023 abroad and 418 in Hungary. In the 2015/2016 financial year we launched seven new product lines in our markets.

Between 1 October 2015 and 30 September 2016, we filed 43 new patent applications and gained 44 patents in Hungary and abroad all in one.